CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
The main purpose of this job is to provide electronic clinical database management from collection and entry to statistical analysis and reporting of data.
The Panel on Research Ethics and the Secretariat on Responsible Conduct of Research are pleased to announce the release of TCPS 2: CORE-2022.
The Frances A Shepherd Award is awarded to investigators or post-graduate trainees, traveling to present CCTG related work at major international meetings where the material has been accepted for presentation. Each award will be approximately $1000 and offered twice a year. Applicants who have had their research accepted for oral or poster presentation at an international scientific meeting and have not received another award to support their travel are eligible to apply.
We are getting closer to the 2022 Virtual CCTG Annual Spring Meeting of Participants which will be held from April 28 - May 01, 2022!
Louise joined the CCTG Patient Representative Committee last year and is supporting the Melanoma & Quality of Life Committees. She is a married mother of five and Nana to 11 who enjoys spending time with her family, gardening and reading. Louise’s background is in Education and has participated as a Patient Partner in many groups and projects on both a National and Provincial level.
"I hope to improve the Patient experience and to encourage cancer patients to be involved in clinical trials and help foster change to improve the future of treatments," says Louise
